Target intelligence / Profile preview

KICSTOR subunit 2 (KICS2)

Target
KICS2
Molecular classification
Other (Component of multiprotein complex), KICSTOR complex subunit, TORC1 regulator, Cytoplasmic protein (non-enzymatic)
01

Overview

KICSTOR subunit 2 (KICS2), encoded by the C12orf66 gene, is a key component of the KICSTOR complex, which comprises four proteins. This complex localizes to the lysosomal membrane and recruits GATOR1, a negative regulator, to suppress mTORC1 signaling under conditions of amino acid or glucose deprivation. Proper mTORC1 inhibition is necessary for controlled cell growth and proliferation. Loss of KICS2 disrupts nutrient sensing and can lead to constitutive mTORC1 activation. KICS2 is widely expressed, with higher levels in endocrine, lymphoid tissues, and early developmental stages, and altered expression in various cancers and neurodevelopmental disorders. KICS2 is not currently a direct drug target, but its pathway (mTOR signaling) is pharmacologically targeted in several disease contexts[1][2][6].

Other names
C12orf66FLJ32549KICSTOR complex protein C12orf66MRT83UPF0536 protein C12orf66
02

Mechanism of action

Not applicable / null (no direct drug targeting KICS2). If considered as part of pathway targeting: mTOR inhibitors block mTORC1 activity, the pathway regulated by KICS2.

03

Biological functions

Negative regulation of mTORC1 signalingCellular response to amino acid starvationCellular response to glucose starvationProtein-protein interaction scaffold (recruits GATOR1 to lysosome)
04

Disease associations

Cancer (most notably colorectal, breast, cervical, leukemia)Neurodevelopmental disorders (e.g., autosomal recessive intellectual developmental disorder 83, developmental and epileptic encephalopathy)Macrocephaly (linked to genomic deletion)
05

Safety considerations

None specified for direct targeting of KICS2Indirect risks may arise from broad mTORC1 pathway inhibition (e.g., immunosuppression, metabolic disturbances with rapalogs)
06

Interacting drugs

None currently approved or established
07

Biomarkers

C12orf66 gene expression (used as part of outcome prediction in colorectal cancer)

Beyond the preview

Go deeper on KICSTOR subunit 2 (KICS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KICSTOR subunit 2 (KICS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call